Ranbaxy assuages stakeholders over Mohali but more to come?
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' top brass has assured stakeholders that the company is doing all it can to set right the concerns raised by the latest US FDA import alert against its Indian site in Mohali, but is keeping mum on reports suggesting its US site may also be facing certain unresolved good manufacturing practice (GMP) compliance issues.